A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
Clinical trial NCT03627195 · COMPLETED
Trial details
- NCT number
- NCT03627195
- Sponsor
- Sumitomo Pharma America, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-07
- Primary completion
- 2019-03-29
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.